Profil at 18th Annual Diabetes Technology Meeting

Profil will be present at the 18th Annual Diabetes Technology Meeting with two posters and a presentation as invited speaker. The Annual DTM will take place from November 8 to November 10, 2018, in North Bethesda, Maryland. We are looking forward to this exciting event.

Read More

Topics: The Science behind Diabetes, Clinical Trial Methods, Diabetes Technology

Posted by Svenya Meister on Oct 29, 2018 5:15:00 PM

Artificial Intelligence to Screen for Diabetic Retinopathy; The Times They Are A-Changin‘.

The far majority of clinical trials in diabetes exclude patients with active retinal disease, as interventions that lower glucose rapidly can temporarily worsen retinopathy. This was originally shown in type 1 diabetes [1] but more recently also in type 2 diabetes [2, 3]. Screening for diabetic retinopathy before inclusion in a clinical trial is relatively cumbersome, also because it often involves a separate visit to an ophthalmologist. The use of a fundus camera with offline interpretation by an ophthalmologist has gained widespread use in clinical practice, but not so much in the field of clinical trials.

In this blog I will briefly describe four recent studies on artificial intelligence approaches to automate the interpretation of retinal images. I will conclude with an outlook on how this may facilitate the screening of potential trial participants for diabetic retinopathy. But first a brief introduction to deep learning, the methodology applied in all these papers.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Hans de Vries on Oct 23, 2018 5:18:00 PM

54th EASD Annual Meeting – Profil’s contributions to the scientific sessions

Berlin, Germany, 1-5 October 2018

Last week our team joined an exciting and busy 54th EASD Annual Meeting in Berlin. We would like to give you a brief overview about those orals and posters presenting results from clinical trials Profil had been involved in.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Dr. Sabine Arnolds on Oct 10, 2018 4:15:43 PM

Profil explores opportunities for artificial pancreas in type 2 diabetes

Highlighting the role of open and trans-sectoral collaboration in the advancement of artificial pancreas solutions

Profil has recently published a peer-reviewed article on the topic of “Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project ” in the Journal of Diabetes Science and Technology. Profil is the organisation coordinating CLOSE. The article is authored by CLOSE industry and academic partners, representatives of the EIT Health public-private partnership management boards, and key opinion leaders in the field.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Oct 2, 2018 5:18:00 PM

Do-It-Yourself Artificial Pancreas systems (DIY APS)

The way forward to closed-loop metabolic control in diabetes care?

The challenge

Diabetes represents a huge and multidimensional challenge. Despite the availability of numerous treatment options, many patents still fail to reach their treatment goals. Administration of  the right amount of insulin at the right time still poses a great challenge for the self-management of many people with diabetes.

Accordingly there is a huge need to implement new innovative products and services improving both the effectiveness of diabetes care and the quality of life for people with diabetes. Particularly user-centered products and sercvices co-created with stakeholders including people with diabetes may have a high potential to increase treatment adherence thereby reducing the enormous pressure on healthcare systems.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Sep 5, 2018 5:16:00 PM

Clamp studies with ultra-long-acting insulins – New challenges for an old procedure

The euglycemic clamp technique has been used as a standard method for assessing time action profiles of insulins for decades. In recent years, new challenges have emerged for investigators performing glucose clamp trials. These are driven by two opposing trends in the development of novel insulins: On the one hand, drug developers are formulating insulin products with a very rapid onset of action and a short duration of action – often referred to as “ultra-rapid insulins” [1,2]. On the other hand, novel basal insulins are being developed with an “ultra-long” duration of action with flatter activity profiles than previously available products [3,4,5].


Read More

Topics: The Science behind Diabetes, Clinical Trials in Diabetes, Diabetes Technology

Posted by Oliver Klein on Jul 24, 2018 5:11:00 PM

Vitamin D supplementation – is there a role in type 1 diabetes?

The possible ‘non-calcemic’ effects of Vitamin D in numerous diseases has become a large area of research. Historically, Vitamin D is known for its regulatory role in calcium absorption and bone metabolism but the identification of vitamin D receptor (VDR) expression in more than 30 tissues led to the possibility of pleiotropic effects of vitamin D [Diabetes Forouhi 2008]. In vitro and animal studies suggested an anti-inflammatory and immunomodulatory effect of Vitamin D [The Review of Diabetic Studies, Gregoriu 2017]. Moreover, preclinical studies uncovered a potential regulatory role of Vitamin D in insulin secretion, β-cell survival and calcium flux in pancreatic β-cells [Mitri J, Endocrinol Metab Clin North Am 2014].

Read More

Topics: The Science behind Diabetes

Posted by Dr. Susanne Famulla on May 30, 2018 4:52:37 PM

Pancreatic ß-cell function changes in response to pharmacological or life-style interventions

Many different approaches are available for measuring Pancreatic ß-cell function (BCF). The choice of testing methodology will ultimately be determined by the research question.

Metabolic dysfunction in pre-diabetes and type 2 diabetes (T2D) leads to a decline in insulin sensitivity (IS) [capacity for glucose disposal and ability to suppress hepatic glucose production in response to insulin]. As an appropriate physiological response, insulin secretion increases in a compensatory manner. Circulating insulin concentrations are reciprocally related to IS through a hyperbolic relationship and are expressed as the “disposition index” [DI: IS * first phase (acute) insulin secretion], which was shown to be highly related to the conversion to T2D [[1]] [[2]] (Figure 1).

Read More

Topics: The Science behind Diabetes

Posted by Dr. Ulrike Hövelmann on Feb 21, 2018 9:27:57 AM

Advanced precision of Continuous Whole Blood Glucose concentration measurements

Continuous Glucose Concentration Measurement

A continuous glucose monitor (CGM) is a sensor that automatically determines the blood glucose concentration at regular intervals (quasi continuous). Typical intervals range from 1 to 15 minutes which equals 60 to 4 glucose values per minute. The blood glucose can be measured directly in the veins (invasive sensors or intra venous (iv)-sensors) or in other body compartments like subcutaneous tissue, tear fluid, saliva (minimal invasive sensors). The most common and commercial available CGMs measure the interstitial glucose concentration and convert the obtained interstitial glucose values to blood glucose values by a suitable calibration.

Read More

Topics: The Science behind Diabetes, Clinical Trials in Diabetes

Posted by Dr. Carsten Benesch on Jan 23, 2018 5:17:00 PM

Bringing glucose clamps up to speed for novel insulins

Ultra-rapid insulins in glucose clamp trials

Euglycemic glucose clamps have been widely accepted as a standard method for describing the time-action profiles of insulins for many years, and clamp results are required by regulatory authorities in the development of new insulin preparation.[1];[2]

The basic principle of a glucose clamp experiment is simple: A patient’s blood glucose (BG) is kept at a constant, predefined level after giving a test dose of insulin. This is achieved by infusing glucose intravenously at a variable rate. Close monitoring of BG levels and frequent adjustment of the glucose infusion rate (GIR) are essential for maintaining the target glucose level (or ‘clamp level’) with as little deviation as possible.

Read More

Topics: The Science behind Diabetes, Clinical Trials in Diabetes

Posted by Oliver Klein on Jan 10, 2018 5:00:00 PM

Subscribe to our monthly blog updates

Find out more: Glucose Clamp Webinar

Subscribe to Email Updates

Our most popular Posts